Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (310)	12/15/1999 10:31:00 AM
From: Micawber	Respond to of 673

Rick: I've been in LGND for over 3 years. As an "abused" shareholder, I agree with your assessment of Robinson, but have always been impressed with the pipeline and the indications. As always, thanks a lot for your input. BPG

To: scaram(o)uche who wrote (310)	12/15/1999 12:36:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 673

Another highly visible biotech.... one that some of us have been critical of..... craters today. ISIP Flapping mouths on CNBC will bad mouth the sector. Nobody will notice that it's fairly easy to put together portfolios that largely avoid these craters.

To: scaram(o)uche who wrote (310)	12/29/1999 2:57:00 PM
From: scaram(o)uche	Respond to of 673

>> I know that the cry is "off label". They need to get a label first. Then they need to find an indication where the off-label use makes sense in light of side effects. << first step in-hand...... this is about as good as the news could have been.... refractory, all stages..... indicates that Regulatory is getting the job done..... good for LGND, good for biotech..... still, another small market..... biz.yahoo.com Wednesday December 29, 2:24 pm Eastern Time Company Press Release FDA Approves Ligand's Targretin Capsules for Early and Advanced-Stage Refractory CTCL